Showing results (11-20 of 16) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Diabetes, Obesity & Metabolism|January 28, 2023
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) studyGrit Andersen, Gursharan Singh, Sundara Moorthi Nainar Murugesan, et al.Expert Opinion on Pharmacotherapy|November 10, 2022
Efficacy and safety of Tregopil, a novel, ultra-rapid acting oral prandial insulin analog, as part of a basal-bolus regimen in type 2 diabetes: a randomized, active-controlled phase 2/3 studyHarold E Lebovitz, Alexander Fleming, Alan D Cherrington, et al.Expert Opinion on Biological Therapy|April 9, 2021
A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19Suresh Kumar, Rosemarie De Souza, Milind Nadkar, et al.Diabetes, Obesity & Metabolism|May 19, 2022
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) studyLeona Plum-Mörschel, Oliver Klein, Gursharan Singh, et al.Expert Opinion on Biological Therapy|October 16, 2025
Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trialJacek C Szepietowski, Adam Reich, Steven R Feldman, et al.Expert Opinion on Biological Therapy|July 25, 2025
Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized, double-blind, Phase 3 STELLAR-2 studyJacek C Szepietowski, Adam Reich, Steven R Feldman, et al.Pageof 2